Pharma News

The parasite Cystoisospora suis causes diarrhea in pigs, especially in newborn piglets, and is capable of quickly spreading across farms. For this reason, pig farmers in Europe preventively use toltrazuril to control parasite development. In contrast to congeneric parasites in chicken, no resistance to this pharmaceutical compound was described in pig parasites until recently. In an article in Parasites & Vectors, researchers of the University of Veterinary Medicine, Vienna, have now for the first time confirmed that toltrazuril is ineffective against a Dutch isolate of the parasite. Even though antiparasitic resistance in pig parasites is developing slowly, monitoring of resistance should be intensified due to the lack of alternative treatment options, and increased hygiene measures should be taken to prevent pathogen spread.When newborn piglets suffer from diarrhea, this is frequently caused by the intestinal parasite Cystoisospora suis.

The settlement resolves claims relating to the classification of EpiPen® Auto-Injector and EpiPen Jr® Auto-Injector for purposes of the Medicaid Drug Rebate Program. The question in the underlying matter was whether the EpiPen products were properly classified with the Centers for Medicare and Medicaid Services ("CMS") as a non-innovator drug under the applicable definition in the Medicaid Rebate statute and subject to the formula that is used to calculate rebates to Medicaid for such drugs. EpiPen Auto-Injector has been classified with CMS as a non-innovator drug since before Mylan acquired the product in 2007 based on longstanding written guidance from the federal government.

Sanofi announced that it filed a patent infringement suit against Merck Sharp & Dohme Corp.  in the United States District Court for the District of New Jersey. In its suit Sanofi alleges infringement of two patents.

Zydus Cadila has received the final approval from the USFDA to market Telmisartan and Hydrochlorothiazide Tablets USP, in the strengths of 40 mg/12.5 mg, 80 mg/12.5 mg, and 80 mg/25 mg.

Iovance Biotherapeutics, Inc a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology,announced that the first patient was dosed in its C-145-04 Phase 2 trial of LN-145 for the treatment of patients with recurrent, metastatic or persistent cervical carcinoma.

Researchers at the Swedish Medical Nanoscience Center at Karolinska Institutet have developed an innovative way of hacking conducting plastics so as to prevent bacterial growth using silver nanoparticles and a small electrical current. The method, which could prove to be useful in preventing bacterial infections in hospitals, is presented in the scientific journal Advanced Healthcare Materials.

Carrying extra weight could raise your risk of heart attack by more than a quarter, even if you are otherwise healthy. Researchers have found that being overweight or obese increases a person’s risk of coronary heart disease (CHD) by up to 28 per cent compared to those with a healthy bodyweight, even if they have healthy blood pressure, blood sugar and cholesterol levels.

Plants have been used to produce a new vaccine against poliovirus in what is hoped to be a major step towards global eradication of the disease.

Anthera Pharmaceuticals announced that the RESULT Phase 3 clinical study of Sollpura for exocrine pancreatic insufficiency due to cystic fibrosis has been approved by the European Cystic Fibrosis Society Clinical Trial Network (ECFS CTN) Executive Committee.

[adsense:336x280:8701650588]

 The global pruritus therapeutic market to grow at a CAGR of 4.95% during the period 2017-2021.Global Pruritus Therapeutic Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.